Lucid Diagnostics (LUCD) Earnings Date & Reports

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LUCD is expected to report earnings to fall 19.00% to -5 cents per share on August 17

Lucid Diagnostics LUCD Stock Earnings Reports

Q2'26

Est.

$-0.06

Q1'26

Est.

$-0.07

Q4'25

Missed

by $0.01

Q3'25

Beat

by $0.01

Q2'25

Beat

by $0.01

The last earnings report on May 14 showed earnings per share of -7 cents, meeting the estimate of -7 cents. With 779.40K shares outstanding, the current market capitalization sits at 189.47M.

View a ticker or compare two or three

Compare

LUCD

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for LUCD